|View printer-friendly version|
|BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update|
Highlights Scientific Advances and Continued Progress for NurOwn® in ALS Towards U.S. FDA Approval;
Following Successful FDA Pre-IND Meeting, BrainStorm will File an IND for NurOwn® in a Second Clinical Indication
Conference Call and Webcast Today at
“We continue to enroll participants in our Phase 3 trial of NurOwn® in ALS, and were delighted by the successful interim safety analysis conducted by the Data Safety Monitoring Board (DSMB),” commented
“Our NurOwn® cellular technology platform has the potential to address the unmet need in other serious neurodegenerative diseases and we are excited to report that following a successful FDA Pre-IND Meeting we are now on track to file an IND in a second clinical indication,” added Mr. Lebovits.
Recent Corporate Highlights:
Financial Results for the Three Months Ended
For further details on Brainstorm’s financials, including financial results for the nine months ended
About BrainStorm Cell Therapeutics Inc.
About NurOwn® Phase 3 Clinical Program in ALS
About U.S. Sites for NurOwn® Phase 3 Trial in ALS